Gemin X Pharmaceuticals
Develops and commercializes targeted cancer therapeutics to improve the lives of patients
About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals was a biopharmaceutical company focused on the development of targeted cancer therapeutics. The company was founded in 1998 as a spin-out from McGill University, with research operations in Montréal, Canada, and executive headquarters in Malvern, Pennsylvania. A key figure in the company's later stage was Glenn J. Gormley, M.D., Ph.D., who joined as President and CEO in June 2008, bringing extensive experience from leadership roles at Novartis, AstraZeneca, and Merck.
The company's core business revolved around creating drugs that reinitiate programmed cell death (apoptosis) and inhibit the metabolism of cancer cells. This approach targeted a variety of hematological and solid tumors. Gemin X's business model was centered on the research and clinical development of its pipeline candidates, with the ultimate goal of commercialization, likely through partnerships or acquisition by a larger pharmaceutical entity. The company successfully raised significant capital through multiple funding rounds, totaling over $100 million by mid-2008 to finance its clinical trials.
Gemin X's product pipeline included several promising candidates. The lead product, obatoclax (GX15-070), was a pan-Bcl-2 inhibitor designed to restore the natural cell death process in cancer cells. It was in Phase II clinical trials for treating conditions like extensive-stage small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Another significant asset was teglarinad (GMX1777), a novel inhibitor of NAD+ synthesis, which had completed Phase 1 studies. The company also had a preclinical telomere capping program.
A major milestone occurred in March 2011, when Cephalon, Inc. announced a definitive agreement to acquire Gemin X for $225 million in cash. The deal also included potential future payments of up to $300 million based on regulatory and sales milestones, bringing the total potential value to $525 million. The acquisition was completed in the second quarter of 2011, at which point Gemin X became a wholly-owned subsidiary of Cephalon.
Source: Dealroom company dataAt a glance
- Founded
- 1997
- Headquarters
- Malvern, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Gemin X Pharmaceuticals in the Malvern ecosystem
The Gemin X Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later10 investors entered at this stage
- CFCaxton Advantage Life Sciences Fund
HBM Partners- PIProQuest Investments
Fonds de solidarité FTQ- MBMerlin Biomed
- SSSB Life Science
VantagePoint Capital Partners
Pinnacle Ventures
HIG Capital
Sanderling Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gemin X Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gemin X Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


